Novo Nordisk to invest billions in new quality control lab
Av The new facility, covering covering 53,000 square meters, will serve as a central hub for quality control operations in Denmark. According to Novo Nordisk the lab is designed to comply with the demands of current and future Good Manufacturing Practice, and also provide the flexibility to support future capacity expansions.
“As we expand our manufacturing capacity and anticipate new products to meet the growing global demand, this new quality control facility will play an important role in ensuring the quality of our products and position us to meet the evolving requirements of patients and regulators”, says Erik Lorin Rasmussen, senior vice president of Product Supply, Aseptic Manufacturing, in a press release.
Construction has begun and is expected to be completed in 2027.
Novo Nordisk has strategic production sites located in Denmark, the US, France, Brazil and China.
Artikeln är en del av vårt tema om News in English.